Profile data is unavailable for this security.
About the company
Sakar Healthcare Limited is an India-based pharmaceutical formulations company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablet, capsule, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages and research & development of above products. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. The Company's product portfolio includes approximately 175 formulations for the international markets, 292 registered brands under its own name in more than 24 therapeutic areas. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. The Company has set up a research-driven vertically integrated with API for oncology formulation manufacturing unit.
- Revenue in INR (TTM)1.56bn
- Net income in INR112.43m
- Incorporated2004
- Employees325.00
- LocationSakar Healthcare Ltd406,Silver Oaks Comm. Complex,Opp. Arun Society, PaldiAHMEDABAD 380007IndiaIND
- Phone+91 7 926584655
- Fax+91 2 717251621
- Websitehttp://www.sakarhealthcare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyka Labs Ltd | 1.18bn | 7.97m | 5.26bn | 423.00 | 807.27 | -- | 45.00 | 4.44 | 0.1826 | 0.1826 | 35.62 | -- | -- | -- | -- | 2,799,802.00 | -- | -5.48 | -- | -8.30 | 60.45 | 60.82 | 0.5065 | -9.16 | -- | 1.36 | -- | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| ZIM Laboratories Ltd | 3.82bn | 179.18m | 5.33bn | 556.00 | 29.82 | -- | 15.33 | 1.40 | 3.67 | 3.67 | 77.81 | -- | -- | -- | -- | 6,867,013.00 | -- | 3.88 | -- | 6.54 | 53.76 | 47.45 | 4.69 | 3.97 | -- | 3.44 | -- | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Medicamen Biotech Ltd | 1.80bn | 81.05m | 5.65bn | 378.00 | 55.08 | -- | 41.83 | 3.13 | 8.11 | 8.11 | 160.31 | -- | -- | -- | -- | 4,772,797.00 | -- | 5.89 | -- | 8.45 | 46.89 | 36.54 | 3.52 | 9.58 | -- | 2.79 | -- | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| Accent Microcell Ltd | 2.45bn | 301.68m | 5.77bn | 174.00 | 14.67 | 3.52 | 16.67 | 2.35 | 18.67 | 18.67 | 126.45 | 77.86 | -- | -- | -- | 14,109,070.00 | -- | -- | -- | -- | 31.00 | -- | 12.29 | -- | 3.42 | -- | 0.0724 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Kilitch Drugs (India) Ltd | 1.51bn | 125.85m | 5.94bn | 168.00 | 47.06 | -- | 42.30 | 3.93 | 7.85 | 7.85 | 94.36 | -- | -- | -- | -- | 9,003,994.00 | -- | 3.38 | -- | 4.76 | 36.87 | 35.33 | 7.03 | 6.17 | -- | 2.63 | -- | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| Sakar Healthcare Ltd | 1.56bn | 112.43m | 7.14bn | 325.00 | 63.16 | -- | 23.95 | 4.59 | 5.20 | 5.20 | 71.95 | -- | -- | -- | -- | 4,784,942.00 | -- | 5.26 | -- | 6.28 | 45.62 | 43.47 | 7.22 | 10.12 | -- | 3.10 | -- | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| IND Swift Laboratories Ltd | 10.04bn | 4.05bn | 7.95bn | 47.00 | 1.96 | -- | 1.79 | 0.7925 | 68.53 | 68.53 | 170.41 | -- | -- | -- | -- | 213,559,000.00 | -- | 5.00 | -- | 6.13 | 47.54 | 41.12 | 40.36 | 8.52 | -- | 4.68 | -- | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Albert David Ltd | 3.60bn | 707.73m | 8.33bn | 1.50k | 11.77 | -- | 10.74 | 2.31 | 124.02 | 124.02 | 630.61 | -- | -- | -- | -- | 2,403,949.00 | -- | 10.00 | -- | 13.15 | 65.26 | 59.85 | 19.67 | 11.87 | -- | 83.07 | -- | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.60bn | 523.05m | 8.69bn | 1.49k | 17.09 | -- | 13.29 | 1.55 | 15.54 | 15.54 | 168.35 | -- | -- | -- | -- | 3,759,038.00 | -- | 11.63 | -- | -- | 49.35 | 42.46 | 9.33 | 7.62 | -- | 1.76 | -- | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 1.50m | 6.90% |
